Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rullo, Anthony F. | - |
dc.contributor.author | Fitzgerald, Kelly J. | - |
dc.contributor.author | Muthusamy, Viswanathan | - |
dc.contributor.author | Liu, Min | - |
dc.contributor.author | Yuan, Cai | - |
dc.contributor.author | Huang, Mingdong | - |
dc.contributor.author | Kim, Minsup | - |
dc.contributor.author | Cho, Art E. | - |
dc.contributor.author | Spiegel, David A. | - |
dc.date.accessioned | 2021-09-04T01:47:31Z | - |
dc.date.available | 2021-09-04T01:47:31Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016-03-07 | - |
dc.identifier.issn | 1433-7851 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89232 | - |
dc.description.abstract | Developing selective strategies to treat metastatic cancers remains a significant challenge. Herein, we report the first antibody-recruiting small molecule (ARM) that is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a uniquely overexpressed cancer cell-surface marker, and facilitating the immune-mediated destruction of cancer cells. A co-crystal structure of the ARM-U2/uPAR complex was obtained, representing the first crystal structure of uPAR complexed with a non-peptide ligand. Finally, we demonstrated that ARM-U2 substantially suppresses tumor growth invivo with no evidence of weight loss, unlike the standard-of-care agent doxorubicin. This work underscores the promise of antibody-recruiting molecules as immunotherapeutics for treating cancer. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-V C H VERLAG GMBH | - |
dc.subject | PLASMINOGEN-ACTIVATOR | - |
dc.subject | BREAST-CANCER | - |
dc.subject | IMMUNOTHERAPY | - |
dc.subject | THERAPY | - |
dc.subject | VACCINE | - |
dc.subject | MICE | - |
dc.subject | UPAR | - |
dc.title | Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cho, Art E. | - |
dc.identifier.doi | 10.1002/anie.201510866 | - |
dc.identifier.scopusid | 2-s2.0-84976253109 | - |
dc.identifier.wosid | 000371521000016 | - |
dc.identifier.bibliographicCitation | ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, v.55, no.11, pp.3642 - 3646 | - |
dc.relation.isPartOf | ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | - |
dc.citation.title | ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | - |
dc.citation.volume | 55 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 3642 | - |
dc.citation.endPage | 3646 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | PLASMINOGEN-ACTIVATOR | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | VACCINE | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordPlus | UPAR | - |
dc.subject.keywordAuthor | antitumor agents | - |
dc.subject.keywordAuthor | cell recognition | - |
dc.subject.keywordAuthor | drug design | - |
dc.subject.keywordAuthor | immunology | - |
dc.subject.keywordAuthor | medicinal chemistry | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.